Test anxiety can significantly impair cognitive performance during dementia screening, potentially leading clinicians to overestimate cognitive decline or even misdiagnose mild cognitive impairment when none exists. The anxiety response triggers the release of cortisol and adrenaline, which physically interfere with the brain regions responsible for memory recall, attention, and processing speed—the exact functions being measured. A 68-year-old woman who had been an accountant for 40 years performed poorly on a memory sequencing test during her first screening appointment, scoring in the range that suggested early-stage dementia.
When she returned six weeks later for a follow-up evaluation at a different facility in a quieter setting with a clinician who took time to explain each task beforehand, her scores improved by 15 percentile points, and subsequent neuropsychological testing showed normal cognitive function for her age. The stakes of this problem extend beyond a single person’s medical record. Anxiety-driven misdiagnosis can lead to unnecessary medication, premature lifestyle changes, loss of driving privileges, or early entry into care facilities—interventions that carry real psychological and social costs. At the same time, anxiety doesn’t mean the screening is invalid; it simply means the conditions under which the test was administered may not reflect a person’s true baseline cognitive abilities.
Table of Contents
- How Does Anxiety Affect Performance on Cognitive Tests?
- The Biological Mechanisms Behind Anxiety’s Cognitive Impact
- Distinguishing Anxiety Effects from True Cognitive Decline
- How to Manage Anxiety Before Dementia Screening
- False Positives, Retesting, and Diagnostic Protocols
- The Role of Test Environment and Clinician Communication
- Anxiety in the Context of Actual Cognitive Decline
- Frequently Asked Questions
How Does Anxiety Affect Performance on Cognitive Tests?
Anxiety narrows attention and consumes working memory resources that would otherwise be devoted to the test tasks themselves. When a person is nervous, part of their cognitive capacity goes toward monitoring physical symptoms—racing heart, dry mouth, trembling hands—and catastrophic thoughts about what poor performance might mean for their future. This divided attention directly reduces the mental resources available for tasks like recalling a list of words, copying geometric shapes, or solving logic problems. Research on test anxiety in healthy younger adults shows performance drops of 5 to 20 percentile points depending on the person’s trait anxiety level and the cognitive domain being tested. Memory tests are particularly vulnerable to anxiety effects because memory retrieval is an effortful process that requires sustained focus. A screening battery might ask a person to memorize a short list of unrelated words and recall them after a delay—a task that is sensitive to both genuine memory problems and to anxiety-induced attention deficits.
The person who is anxious may fail to encode the information deeply during the learning phase simply because they were worried rather than fully present. This looks, on paper, like a memory impairment when it is actually an encoding problem caused by divided attention. Processing speed tests are also highly susceptible to anxiety effects. These tests measure how quickly a person can complete simple perceptual or cognitive operations, such as matching symbols to numbers or identifying patterns. An anxious person may work more slowly and carefully, trying not to make mistakes, or may rush and make careless errors. Either way, the score reflects anxiety-driven performance strategy, not the person’s actual neural processing capacity.
The Biological Mechanisms Behind Anxiety’s Cognitive Impact
When someone perceives a situation as threatening or evaluative—and cognitive testing certainly feels evaluative—the amygdala, a small almond-shaped structure deep in the brain, triggers a cascade of hormonal and neurological changes. Cortisol and adrenaline flood the bloodstream within seconds. Simultaneously, the prefrontal cortex, which governs executive function and complex reasoning, receives less blood flow and activation. This is the brain’s threat-response system working as designed: it prioritizes survival and vigilance over deliberate thinking. The prefrontal cortex is critical for working memory, which is needed to hold and manipulate information during problem-solving and reasoning tasks. A person taking a test of verbal fluency—asked to name as many animals as possible in one minute—may find themselves mentally frozen not because they have aphasia or dementia, but because their working memory has been depleted by the physiological anxiety response.
The effect is temporary and reversible; once anxiety decreases, working memory capacity returns. However, a clinician who sees only the single test score and doesn’t know about the person’s anxiety during testing may misinterpret it as evidence of cognitive decline. This is a major limitation of single-session cognitive screening if the testing environment or the person’s emotional state is not documented. Additionally, high anxiety can impair sleep quality in the nights before a scheduled screening appointment. Poor sleep itself causes measurable deficits in attention, processing speed, and memory consolidation that can persist for days. A person who felt anxious and slept poorly for three nights before their dementia screening may perform 10 to 15 percentile points below their actual baseline, compounding the direct anxiety effects during the test itself.
Distinguishing Anxiety Effects from True Cognitive Decline
One of the most challenging aspects of dementia screening is that some symptoms of anxiety disorder and some early cognitive changes can look similar. Both anxiety and mild cognitive impairment can present with forgetfulness, difficulty concentrating, and slowed processing. A person with generalized anxiety disorder may complain of memory problems and perform poorly on memory tests—yet their actual memory system is intact, and the problems resolve when anxiety is treated. Conversely, someone with early Alzheimer’s disease may also be anxious about their cognitive changes, making it hard to disentangle which symptoms are caused by anxiety and which are caused by neurodegeneration. Clinicians use several strategies to untangle this. A comprehensive screening typically includes not just cognitive tests but also a detailed history from both the person and an informant (family member or close friend) who can describe whether cognitive changes have been progressive and noticeable over months or years. The Mini-Cog, a brief screening tool, includes a depression and anxiety assessment component to flag these comorbidities.
Neuropsychological batteries administered by specialists include many subtests of the same cognitive domain, so a single weak performance on one task is less likely to be misinterpreted as evidence of decline. However, a limitation of primary care dementia screening is that it often relies on brief instruments administered in a time-pressured appointment, sometimes without an informant present. In these contexts, an anxious person’s poor performance is more likely to be misattributed to cognitive decline. The person might not report their anxiety, or the clinician might not probe for it, or there might not be enough time for a follow-up conversation that would clarify the picture. A 72-year-old man presented to his primary care physician with a complaint from his wife that he seemed forgetful. He scored below the cutoff on a standard screening tool, but when asked about his mood, he disclosed that he had been having panic attacks and severe anxiety about his health for the past several months. Repeat testing after treating his anxiety disorder with an SSRI showed normal cognitive performance.
How to Manage Anxiety Before Dementia Screening
Several practical steps can reduce anxiety during cognitive screening and improve the reliability of results. First, being informed about what to expect reduces the unknown and therefore reduces anxiety. When a person knows they will be asked to memorize and recall a list of words, name objects in a picture, or solve pattern puzzles, they are less likely to experience a startle response or feel blindsided. Some clinicians provide a brief pre-test explanation; others have written materials explaining the screening process. Asking the person to bring a family member or friend for support can also help by providing emotional reassurance and a familiar presence. The testing environment itself matters. A quiet, comfortable room with minimal distractions is standard practice for formal neuropsychological testing but may not always be available in a busy primary care office.
A person being screened in a room with hospital sounds audible through the walls or with frequent interruptions from clinic staff will experience more anxiety than someone in a calm private space. Timing also matters; a screening done early in the day, when a person is alert and less fatigued, is often better tolerated than one done late in the day or when a person is exhausted. The demographer skills of the clinician matter as well. A clinician who takes time to explain each task, reassures the person that there are no “trick” questions, and acknowledges that testing can feel uncomfortable creates a lower-anxiety testing environment than one who is rushed or perfunctory. The tone of the interaction—whether the person feels respected and understood or rushed and judged—influences their anxiety level and therefore their performance. A tradeoff is that more time spent on a detailed testing environment reduces clinic efficiency, which is why comprehensive cognitive assessment by a neuropsychologist (which takes several hours) is different from a 5-minute screening in a doctor’s office. The screening is fast but has more room for anxiety effects to distort results.
False Positives, Retesting, and Diagnostic Protocols
A positive screening result (one that suggests cognitive impairment) does not automatically mean a person has dementia or even mild cognitive impairment. Screening tools are designed to be sensitive but not specific—they catch most people with cognitive problems but also generate false positives, and anxiety is one major source of false positives. When a person screens positive, best practice includes retesting after an interval, sometimes with a different test or in a different setting, to see whether the impairment persists or was a one-time performance dip. The problem is that false positives can cause real harm before retesting happens. A person who is told they may have dementia may panic, tell their family, alter their behavior, or make decisions prematurely.
Some people experience a cascade effect where anxiety from the screening result causes worse performance on retesting, making the false positive seem more credible. Additionally, in healthcare systems with limited neuropsychology resources or where cognitive screening is done only once, a person might never get the retesting that would clarify whether their initial impairment was real or anxiety-driven. This is a significant limitation of screening protocols that lack follow-up procedures. Guidelines from organizations like the American Academy of Neurology recommend that a single abnormal score on a cognitive screening test in an asymptomatic person should not be treated as a diagnosis; it should prompt further evaluation. Yet in practice, many people receive a diagnosis or a strong suggestion of cognitive impairment based on a single screening encounter, sometimes without the person or their family understanding that retesting might show different results.
The Role of Test Environment and Clinician Communication
The physical and interpersonal context of testing has measurable effects on cognitive performance. Research using functional MRI has shown that when people are told a task is a test of ability, they show greater amygdala activation and less prefrontal cortex activation compared to when they are told the same task is a practice exercise. The difference in brain activation is accompanied by measurable performance decrements.
This “stereotype threat” phenomenon has been documented in many populations and demonstrates that the framing and presentation of a cognitive task, not just the task itself, influences performance. In dementia screening, the framing is often explicitly evaluative: “I’m going to ask you some questions to check your thinking and memory.” This language is medically accurate, but it also primes the person to experience the situation as a judgment of their cognitive abilities, which increases anxiety. An alternative framing—”I’m going to ask you to do some activities that help me understand how your thinking and memory are working”—is equally accurate but may create less anxiety. Some clinicians are intentionally trained to use low-threat language and to normalize test anxiety by saying things like, “These tasks can feel a little challenging, and that’s normal.” Others do not receive this training.
Anxiety in the Context of Actual Cognitive Decline
One important nuance is that a person can have both anxiety and genuine cognitive impairment, and anxiety can sometimes exacerbate or mask the true extent of cognitive decline. A person in the early stages of Alzheimer’s disease may also develop anxiety as they become aware of their cognitive changes, leading to a dual diagnosis situation. In these cases, the anxiety does not explain away the cognitive decline; rather, it adds another layer of complexity to the clinical picture.
Additionally, anxiety itself, when chronic and untreated, can contribute to cognitive decline over time through multiple mechanisms including elevated cortisol levels, sleep disruption, and reduced engagement in cognitively stimulating activities. A person with long-standing anxiety disorder who is screened for dementia may have some degree of genuine cognitive impact from the anxiety itself, separate from any dementia pathology. This means that screening positive for cognitive problems due to anxiety is not entirely benign; it may indicate a need to address the anxiety through treatment, even if dementia is not present.
- —
Frequently Asked Questions
Can anxiety cause me to fail a dementia screening test?
Yes. Anxiety activates the amygdala and reduces prefrontal cortex function, which directly impairs memory, attention, and processing speed—the exact capacities being tested. Performance can drop 5 to 20 percentile points depending on anxiety levels.
Should I take medication to calm down before a dementia screening?
Do not take medication without talking to your doctor first. However, discussing your anxiety with your clinician beforehand is important; they may recommend relaxation techniques or adjust the testing environment. Some clinicians prefer testing without anxiety medication so they see your baseline state, while others accommodate anxiety management.
What if I score low on a dementia screening test because of anxiety?
One low score is not a diagnosis. Best practice includes retesting after an interval or referral to neuropsychological testing in a controlled setting. If you know anxiety was affecting your performance, tell your clinician so they can account for it.
Can anxiety and early dementia happen at the same time?
Yes. Some people with early cognitive changes develop anxiety about their memory. In these cases, treating the anxiety doesn’t make the cognitive impairment go away, but it can make symptoms easier to assess and manage.
How can I reduce anxiety during a dementia screening?
Ask your clinician to explain the testing process beforehand, request a quiet private setting, bring a family member for support if allowed, and be honest about feeling nervous. A clinician who takes time to reassure you will help lower anxiety naturally.
Why might I perform better on a dementia screening the second time if I failed the first time?
Familiarity with the testing process reduces anxiety, and anxiety reduction improves cognitive performance. Anxiety-driven false positives often improve on retesting. However, if cognitive impairment is real, you may perform similarly or worse on retesting depending on the condition. —
